Literature DB >> 25728839

Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.

Sandra P Toelle1, Andrea Poretti1,2, Peter Weber3, Tatjana Seute4, Jacoline E C Bromberg5, Ianina Scheer6, Eugen Boltshauser7.   

Abstract

Unidentified bright objects (UBO) and tumors are well-known cerebellar abnormalities in neurofibromatosis type 1 (NF1). Literature reports on malformative cerebellar anomalies in neurofibromatosis type 1 (NF1), however, are scant. We retrospectively studied the clinical and neuroimaging findings of 5 patients with NF1 (4 females, age 6 to 29 years at last follow-up) and cerebellar anomalies. Cerebellar symptoms on neurological examination were mild or even not evident whereas learning disabilities were more or less pronounced in four patients. Two patients had cerebellar hypoplasia (diffusely enlarged cerebellar interfoliar spaces) and three cerebellar dysmorphias involving mainly one cerebellar hemisphere. In NF1, malformative cerebellar anomalies are rare (estimated prevalence of about 1%), but most likely underestimated and easily overlooked, because physicians tend to focus on more prevalent, obvious, and well-known findings such as optic pathway gliomas, other tumors, and UBO. This kind of cerebellar anomaly in NF1 has most likely a malformative origin, but the exact pathogenesis is unknown. The individual clinical significance is difficult to determine. We suggest that cerebellar anomalies should be systematically evaluated in neuroimaging studies of NF1 patients.

Entities:  

Keywords:  Cerebellar dysmorphia; Cerebellar hypoplasia; Cerebellum; Neurofibromatosis type 1; Neuroimaging

Mesh:

Year:  2015        PMID: 25728839     DOI: 10.1007/s12311-015-0658-8

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  35 in total

1.  Clinical spectrum associated with cerebellar hypoplasia.

Authors:  Evangeline Wassmer; Paul Davies; William P Whitehouse; Stuart H Green
Journal:  Pediatr Neurol       Date:  2003-05       Impact factor: 3.372

2.  Cerebral vasculopathy in children with neurofibromatosis type 1.

Authors:  Partha S Ghosh; A David Rothner; Todd M Emch; Neil R Friedman; Manikum Moodley
Journal:  J Child Neurol       Date:  2012-04-24       Impact factor: 1.987

3.  Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study.

Authors:  Jonathan M Payne; Tania Pickering; Melanie Porter; Emily C Oates; Navdeep Walia; Kristina Prelog; Kathryn N North
Journal:  Am J Med Genet A       Date:  2013-12-19       Impact factor: 2.802

4.  Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1.

Authors:  Joel A Champion; Kristy J Rose; Jonathan M Payne; Joshua Burns; Kathryn N North
Journal:  Dev Med Child Neurol       Date:  2014-01-04       Impact factor: 5.449

5.  Unilateral cerebellar hypoplasia with different clinical features.

Authors:  Gulcin Benbir; Simay Kara; Beyza Citci Yalcinkaya; Geysu Karhkaya; Beyhan Tuysuz; Naci Kocer; Cengiz Yalcinkaya
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

6.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

Authors:  Shelley L Hyman; E Arthur Shores; Kathryn N North
Journal:  Dev Med Child Neurol       Date:  2006-12       Impact factor: 5.449

7.  Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1).

Authors:  D H Gutmann; S A Rasmussen; P Wolkenstein; M M MacCollin; A Guha; P D Inskip; K N North; M Poyhonen; P H Birch; J M Friedman
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

8.  Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1.

Authors:  Bonnie Kaas; Thierry A G M Huisman; Aylin Tekes; Amanda Bergner; Jaishri O Blakeley; Lori C Jordan
Journal:  J Child Neurol       Date:  2012-07-25       Impact factor: 1.987

9.  Prenatal unilateral cerebellar hypoplasia in a series of 26 cases: significance and implications for prenatal diagnosis.

Authors:  M Massoud; M Cagneaux; C Garel; N Varene; M-L Moutard; T Billette; A Benezit; C Rougeot; J-M Jouannic; J Massardier; P Gaucherand; V Desportes; L Guibaud
Journal:  Ultrasound Obstet Gynecol       Date:  2014-10       Impact factor: 7.299

10.  Update from the 2013 International Neurofibromatosis Conference.

Authors:  Scott R Plotkin; Anne C Albers; Dusica Babovic-Vuksanovic; Jaishri O Blakeley; Xandra O Breakefield; Courtney M Dunn; D Gareth Evans; Michael J Fisher; Jan M Friedman; Marco Giovannini; David H Gutmann; Michel Kalamarides; Andrea I McClatchey; Ludwine Messiaen; Helen Morrison; David B Parkinson; Anat O Stemmer-Rachamimov; Catherine D Van Raamsdonk; Vincent M Riccardi; Tena Rosser; Aaron Schindeler; Miriam J Smith; David A Stevenson; Nicole J Ullrich; Thijs van der Vaart; Brian Weiss; Brigitte C Widemann; Yuan Zhu; Annette C Bakker; Alison C Lloyd
Journal:  Am J Med Genet A       Date:  2014-09-24       Impact factor: 2.802

View more
  2 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Terminology in morphological anomalies of the cerebellum does matter.

Authors:  Andrea Poretti; Eugen Boltshauser
Journal:  Cerebellum Ataxias       Date:  2015-07-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.